Last updated: February 27, 2026
What is NDC 81033-0029?
NDC 81033-0029 refers to a specific drug product, identified by the National Drug Code (NDC). This code is assigned to a medication registered for commercial distribution. Based on available data, this NDC corresponds to Duloxetine Capsules 30 mg. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated primarily for depression, anxiety, and neuropathic pain.
Market Overview
Market Size and Trends
The global antidepressants market was valued at approximately USD 16.4 billion in 2021 and is projected to reach USD 24.1 billion by 2028, growing at a CAGR of 6.1% (Vantage Market Research, 2022). Duloxetine accounts for an estimated 10-15% of this market, with US sales constituting roughly 65% of global revenue.
In the US, Duloxetine's annual sales reached USD 1.2 billion in 2022, driven by high prescription rates for depression and neuropathic pain. The medication's usage continues to rise due to broadening indications and increasing awareness of mental health issues.
Competition Landscape
Key competitors include:
- Venlafaxine (Effexor)
- Sertraline (Zoloft)
- Escitalopram (Lexapro)
- Pregabalin (Lyrica)
- Gabapentin
Duloxetine's differentiation lies in its dual action on depression and pain syndromes, enabling cross-therapy applications.
Regulatory Factors
Duloxetine has FDA approval for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia. Recent regulatory discussions focus on patent expirations, generic entry, and new formulation approvals, impacting market shares.
Price Projections
Current Pricing Data
As of Q2 2023, the average wholesale price (AWP) per 30 mg capsule is approximately USD 5.50. Retail pharmacies typically sell this for USD 7.00 to USD 9.50 per capsule, depending on discounts and pharmacy margins.
Generic availability: Since patent expiration in 2013, multiple generics have entered the market, significantly reducing the price.
| Pricing Parameter |
USD per Capsule |
Notes |
| Wholesale Acquisition Cost (WAC) |
USD 4.20 |
Approximate for generic Duloxetine |
| Retail Price (cash) |
USD 8.00 - 9.50 |
Retail price varies by location |
| Medicare Part D reimbursement |
USD 6.50 per capsule |
Average reimbursement rate |
Price Trends and Projections
Over the past five years, the average price per capsule declined from USD 10.00 to USD 7.00, driven mainly by generic competition. The trend is expected to continue, albeit at a slower pace, due to patent cliff effects and market saturation.
Forecast for 2025-2030:
- The price for a 30 mg capsule is projected to stabilize around USD 6.00 to USD 7.00, assuming patent protections remain weak and generic penetration continues.
- Price elasticity suggests that further reductions may occur if new formulations or biosimilars are approved.
External Factors Influencing Price
- Patent expirations: The primary patent's expiration in 2013 led to increased generic availability, pressuring prices downward.
- Regulatory approvals: Introduction of extended-release formulations or combination therapies could alter pricing dynamics.
- Market penetration in emerging regions: Growing markets in Asia and Latin America might see lower prices due to less stringent regulation and lower purchasing power.
Future Market Drivers
- Increased diagnosis rates of depression and chronic pain.
- Expansion of indications, such as fibromyalgia, influencing demand.
- Competitive pricing pressures from biosimilars and generics.
- Technological innovations, including once-daily formulations, that could command higher prices.
Risks Affecting Market and Pricing
- Patent challenges and patent cliffs.
- Entry of new, more effective therapies.
- Changes in healthcare policies, such as price controls or formulary restrictions.
- Shifts in prescribing practices favoring newer medications.
Summary of Key Data Points
| Data Point |
Value / Range |
Source |
| US 2022 Duloxetine sales |
USD 1.2 billion |
IQVIA |
| Average capsule price (2023) |
USD 7.00 - 9.50 |
Independent pharmacy survey |
| Generic WAC (2023) |
USD 4.20 |
Red Book, First Databank |
| Market CAGR (2022-2028) |
6.1% |
Vantage Market Research |
| Price projection (2025-2030) |
USD 6.00 - USD 7.00 per capsule |
Market analysis |
Key Takeaways
- The drug represented by NDC 81033-0029 is Duloxetine capsules, heavily influenced by generic entry.
- The US market for Duloxetine is mature, with prices declining to under USD 7.00 per capsule, stabilizing when patent protections lapse.
- Future price trends will depend on regulatory developments, market saturation, and potential new formulations.
- Market growth will be driven by rising mental health awareness and expanding indications, though price competitiveness remains a crucial factor.
FAQs
Q1: When is the patent for Duloxetine set to expire?
A: The original patent expired in 2013, opening the market to generics.
Q2: How does the availability of generics impact pricing?
A: Increased generic competition typically reduces prices, with WAC decreasing by approximately 50% post-patent expiry.
Q3: What are the main drivers for market growth in Duloxetine?
A: Rising prevalence of depression and chronic pain, expanded indications, and ongoing awareness campaigns.
Q4: Could new formulations influence future prices?
A: Yes. Extended-release or combination therapies could command higher prices, potentially offsetting downward pressure.
Q5: What regional factors influence global prices?
A: Regulatory environments, healthcare infrastructure, and market penetration differ; prices tend to be higher in the US and Europe compared to emerging markets.
Sources:
- Vantage Market Research. (2022). Global Antidepressants Market Size, Share & Trends.
- IQVIA. (2022). U.S. Prescription Drug Sales Data.
- Red Book. (2023). Drug Pricing Data.
- FDA. (2013). Duloxetine Patent Expiration and Generic Approval Timeline.
- First Databank. (2023). Pharmacy Pricing and Reimbursement Data.
